API business Development
Sale of APIs and Pharmaceutical intermediates to most of Japanese pharmaceutical companies ・Number of Japanese pharmaceutical companies, with whom we are providing： 40 companies
With recent frequent revision of National Healthcare Insurance drug prices, it is a must that Japanese pharmaceutical companies reduce manufacturing costs of finished products in order to survive in the pharmaceutical market. Therefore, it is crucial that they secure profit by replacing current supply sources’ APIs with new ones, whose prices are cheaper than the current ones.
We can grasp pharmaceutical companies, who have high motivations for the replacement, and grasp APIs, which are subject to the replacement, making use of database.
Based on market information from database, we can provide Japanese pharmaceutical companies with foreign APIs efficiently.
We can make not only generic pharmaceutical products’ market researches but also originators’ pharmaceutical products’ market researches, for which products any generic pharmaceutical products have not been marketed.
We can also provide patent information to both foreign API suppliers and Japanese pharmaceutical companies.
We attend audits for foreign API manufacturers, conducted by Japanese pharmaceutical companies and PMDA.
We also make GMP level checks for foreign API manufacturers before Japanese pharmaceutical companies and PMDA.
Our staff, who has much experiences in auditing foreign API manufacturers, in our company makes GMP level checks and gives foreign API manufacturers proper advices.
We also do businesses to develop APIs with Japanese API manufacturers, using crude APIs or API intermediates, which are imported to Japan by us.
We import not only APIs but also API intermediates and distribute good reasonable API intermediates to Japanese API manufacturers.
We have contributed to reduce API prices, distributing good reasonable API intermediates to not only Japanese API manufacturers but also foreign API manufacturers.
